Colfax Corporation Announces Fourth Quarter and Full Year 2021 Results
Colfax Corporation (NYSE: CFX) reported its Q4 and full-year 2021 financial results, noting net income from continuing operations at $10 million ($0.06 EPS) and adjusted EPS of $0.59, a 16% increase from last year. Q4 sales rose 24% to $1,023 million, with operating income at $55 million. Full-year operating cash flow reached $356 million, and free cash flow was $277 million. The company is set to separate into two independent entities, Enovis and ESAB, in Q1 2022, with strong growth projections for both. Enovis anticipates a 10-14% sales increase in 2022, while ESAB expects 7-10% organic growth.
- Adjusted EPS rose 16% to $0.59 year-over-year.
- Q4 sales increased by 24% to $1,023 million.
- Operating cash flow for the year was $356 million.
- Free cash flow reached $277 million for the year.
- Separation into two independent companies is progressing as planned.
- Net income from continuing operations dropped to $10 million from $41 million year-over-year.
- Operating income in Q4 decreased to $55 million from $58 million in the prior year quarter.
- Adjusted EBITA margins decreased by 30 basis points to 13.3%.
- Strong operating performance supported
$0.06 EPS from continuing operations and$0.59 of adjusted EPS - Achieved a strong quarter of cash flow, contributing to full year operating cash flow of
$356 million and free cash flow of$277 million - Positioned for separation into two independent public companies near the end of the first quarter 2022 with strong growth outlooks for both businesses
Wilmington, DE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the fourth quarter and fiscal year 2021 and provided additional updates.
The Company reported fourth quarter net income from continuing operations of
In the fourth quarter, sales of
Medical Technology segment sales of
“We delivered a strong quarter and year of financial results with both businesses continuing to outperform their respective markets,” said Matt Trerotola, Colfax President and CEO. “ESAB effectively executed in a period of inflationary and supply chain pressures to deliver solid growth and operating margin expansion. Our MedTech business drove double-digit organic growth versus 2020, and we delivered organic growth versus 2019 despite on-going pandemic challenges. As we exit this pivotal year and approach our separation date, I am confident that both businesses are operationally and strategically well-positioned to accelerate growth and create long-term shareholder value.”
Separation Update
The Company reported that it has completed most steps in preparation for the tax-free spin-off of its ESAB business to Colfax shareholders near the end of the first quarter, subject to obtaining final approval from the Board of Directors and market, regulatory and other customary conditions. Colfax intends to distribute
“Upon separation, both of these leading businesses will have the financial flexibility to achieve their long-term strategic goals of accelerating growth, expanding margins and generating cash flow to create long-term shareholder value”, said Mr. Trerotola.
The determination of the respective boards of directors is nearly complete for both ESAB and Colfax, which will be renamed Enovis at the time of separation. The boards will include existing Colfax directors and new directors with skills and perspectives that are relevant to each company. Mitch Rales, current Colfax Chairman, is expected to serve as Chairman of both business’ boards.
2022 Financial Outlook
Colfax reported that it expects strong sales and profit growth in 2022 for both of its businesses with typical seasonal patterns and improving business conditions as the year progresses. Enovis is projecting sales to grow 10
Investor Calls Scheduled for Monday, March 14, 2022
In anticipation of the separation of Colfax being completed near the end of the first quarter of 2022, Enovis and ESAB each announced investor calls scheduled for Monday, March 14, 2022 to discuss their respective strategies for value creation including 2022 forecasted performance. ESAB CEO Shyam Kambeyanda and his team will present from 9:00 a.m. to 10:30 a.m. Eastern time, followed by a thirty-minute break and then a presentation by Enovis CEO Matt Trerotola and his team from 11:00 a.m. to approximately 1:00 p.m. Eastern time. For more information, please visit the Investor Relations section of our website https://ir.colfaxcorp.com/events-presentations.
Conference Call and Webcast
The Company will hold a conference call to discuss its fourth quarter and fiscal year 2021 results beginning at 8:00 a.m. Eastern on Tuesday, February 22, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 7466839 and through webcast via Colfax’s website www.colfaxcorp.com under the “Investors” section. Access to a supplemental slide presentation can also be found at the Colfax website under the same heading. Both the audio of this call and the slide presentation will be archived on the website later today and will be available until the next quarterly call.
About Colfax Corporation
Colfax Corporation (NYSE: CFX) is a leading diversified technology company that provides orthopedic and fabrication technology products and services to customers around the world, principally under the DJO and ESAB brands. The Company uses its Colfax Business System, a comprehensive set of tools and processes, to create superior value for customers, stockholders and associates. In March of 2021, Colfax announced its intention to separate into two independent and public companies, which is targeted to be completed near the end of the first quarter of 2022, to accelerate strategic momentum and unlock additional value creation potential. Enovis Corporation will focus on medical technologies and ESAB Corporation will focus on fabrication technologies. For more information about Colfax and our separation activities, please visit www.colfaxcorp.com.
Non-GAAP Financial Measures and Other Adjustments
Colfax has provided in this press release financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income margin from continuing operations, adjusted net income per diluted share from continuing operations, adjusted EBITA (earnings before interest, taxes and amortization), adjusted EBITDA (adjusted EBITA plus depreciation and other amortization), adjusted EBITA margin, organic sales growth, and free cash flow. Colfax also provides adjusted EBITA and adjusted EBITA margin on a segment basis.
Adjusted net income from continuing operations represents net income (loss) from continuing operations excluding restructuring and other related charges, European Union Medical Device Regulation (“MDR”) and other costs, pension settlement gain, debt extinguishment charges, acquisition-related amortization and other non-cash charges, and strategic transaction costs. Adjusted net income includes the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Colfax also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations.
Adjusted net income per diluted share from continuing operations represents adjusted net income from continuing operations divided by the number of adjusted diluted weighted average shares. Both GAAP and non-GAAP diluted net income per share data are computed based on weighted average shares outstanding and, if there is net income from continuing operations (rather than net loss) during the period, the dilutive impact of share equivalents outstanding during the period. Diluted weighted average shares outstanding and adjusted diluted weighted average shares outstanding are calculated on the same basis except for the net income or loss figure used in determining whether to include such dilutive impact.
Adjusted EBITA represents net income (loss) from continuing operations excluding restructuring and other related charges, MDR and other costs, acquisition-related amortization and other non-cash charges, and strategic transaction costs, as well as income tax expense (benefit) and interest expense, net. Colfax presents adjusted EBITA margin, which is subject to the same adjustments as adjusted EBITA. Further, Colfax presents adjusted EBITA (and adjusted EBITA margin) on a segment basis, which excludes the impact of strategic transaction costs and acquisition-related amortization and other non-cash charges from segment operating income.
Organic sales growth (decline) excludes the impact of acquisitions and foreign exchange rate fluctuations.
Organic sales-per-day growth (decline) represents Organic sales growth (decline) adjusted for additional or fewer selling days calculated based on the global average selling days particular to each segment.
Free cash flow represents cash flow from operating activities excluding cash outflows related to the planned separation, less purchases of property, plant and equipment net proceeds from sale of certain properties.
These non-GAAP financial measures assist Colfax management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Colfax management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this press release.
CAUTIONARY NOTE CONCERNING FORWARD LOOKING STATEMENTS
This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax’s plans, objectives, outlook, expectations and intentions, including the intended separation of Colfax’s fabrication technology and specialty medical technology businesses (the “Separation”), and the timing, method and anticipated benefits of the Separation, and other statements that are not historical or current fact. Forward-looking statements are based on Colfax’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax’s results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic, including the rise, prevalence and severity of variants of the virus, actions by governments, businesses and individuals in response to the situation, such as the scope and duration of the outbreak, the nature and effectiveness of government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions, the impact on creditworthiness and financial viability of customers; risks relating to the Separation, including the final approval of the Separation by Colfax’s board of directors, the uncertainty of obtaining regulatory approvals, and a favorable tax opinion, Colfax’s ability to satisfactorily complete steps necessary for the Separation and related transactions to be generally tax-free for U.S. federal income tax purposes, the ability to satisfy the necessary conditions to complete the Separation on a timely basis, or at all, the ability to realize the anticipated benefits of the Separation, developments related to the impact of the COVID-19 pandemic on the Separation, and the financial and operating performance of each company following the Separation; other impacts on Colfax’s business and ability to execute business continuity plans; and the other factors detailed in Colfax’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Colfax’s filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Colfax disclaims any duty to update the information herein.
The term “Colfax” in reference to the activities described in this press release may mean one or more of Colfax’s global operating subsidiaries and/or their internal business divisions and does not necessarily indicate activities engaged in by Colfax Corporation.
Contact:
Mike Macek
Vice President, Finance
Colfax Corporation
+1-302-252-9129
investorrelations@colfaxcorp.com
Colfax Corporation
Consolidated Statements of Operations
Dollars in thousands, except per share data
(Unaudited)
| Three Months Ended | Year Ended | ||||||||||||||
| December 31, 2021 | December 31, 2020 | December 31, 2021 | December 31, 2020 | ||||||||||||
| Net sales | $ | 1,023,273 | $ | 828,122 | $ | 3,854,303 | $ | 3,070,769 | |||||||
| Cost of sales | 604,547 | 473,437 | 2,240,645 | 1,782,664 | |||||||||||
| Gross profit | 418,726 | 354,685 | 1,613,658 | 1,288,105 | |||||||||||
| Selling, general and administrative expense | 351,665 | 281,417 | 1,329,376 | 1,087,401 | |||||||||||
| Restructuring and other related charges | 11,656 | 14,824 | 27,639 | 38,413 | |||||||||||
| Operating income | 55,405 | 58,444 | 256,643 | 162,291 | |||||||||||
| Pension settlement gain | — | — | (11,208) | — | |||||||||||
| Interest expense, net | 15,588 | 25,615 | 72,593 | 104,262 | |||||||||||
| Debt extinguishment charges | — | — | 29,870 | — | |||||||||||
| Income from continuing operations before income taxes | 39,817 | 32,829 | 165,388 | 58,029 | |||||||||||
| Income tax expense (benefit) | 28,274 | (8,691) | 66,695 | (6,053) | |||||||||||
| Net income from continuing operations | 11,543 | 41,520 | 98,693 | 64,082 | |||||||||||
| Loss from discontinued operations, net of taxes | (12,064) | (7,405) | (22,415) | (18,311) | |||||||||||
| Net income | (521) | 34,115 | 76,278 | 45,771 | |||||||||||
| Less: income attributable to noncontrolling interest, net of taxes | 1,386 | 903 | 4,621 | 3,146 | |||||||||||
| Net income (loss) attributable to Colfax Corporation | $ | (1,907) | $ | 33,212 | $ | 71,657 | $ | 42,625 | |||||||
| Net income (loss) per share – basic | |||||||||||||||
| Continuing operations | $ | 0.06 | $ | 0.30 | $ | 0.61 | $ | 0.45 | |||||||
| Discontinued operations | $ | (0.07) | $ | (0.05) | $ | (0.15) | $ | (0.13) | |||||||
| Consolidated operations | $ | (0.01) | $ | 0.24 | $ | 0.47 | $ | 0.31 | |||||||
| Net income (loss) per share – diluted | |||||||||||||||
| Continuing operations | $ | 0.06 | $ | 0.29 | $ | 0.60 | $ | 0.44 | |||||||
| Discontinued operations | $ | (0.07) | $ | (0.05) | $ | (0.15) | $ | (0.13) | |||||||
| Consolidated operations | $ | (0.01) | $ | 0.24 | $ | 0.46 | $ | 0.31 | |||||||
Colfax Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions, except per share data
(Unaudited)
| Three Months Ended | Year Ended | ||||||||||||||
| December 31, 2021 | December 31, 2020 | December 31, 2021 | December 31, 2020 | ||||||||||||
| Adjusted Net Income and Adjusted Net Income Per Share | |||||||||||||||
| Net income from continuing operations attributable to Colfax Corporation (1) (GAAP) | $ | 10.2 | $ | 40.6 | $ | 94.1 | $ | 60.9 | |||||||
| Restructuring and other related charges - pretax (2) | 16.9 | 16.5 | 32.9 | 45.0 | |||||||||||
| MDR and other costs - pretax (3) | 2.4 | 2.4 | 7.9 | 6.9 | |||||||||||
| Debt extinguishment charges – pretax | — | — | 29.9 | — | |||||||||||
| Acquisition-related amortization and other non-cash charges - pretax (4) | 44.8 | 35.8 | 163.6 | 143.9 | |||||||||||
| Strategic transaction costs - pretax (5) | 16.7 | (0.4) | 44.0 | 2.8 | |||||||||||
| Pension settlement gain – pretax | — | — | (11.2) | — | |||||||||||
| Tax adjustment (6) | 5.1 | (24.4) | (28.9) | (65.8) | |||||||||||
| Adjusted net income from continuing operations (non-GAAP) | $ | 96.0 | $ | 70.6 | $ | 332.3 | $ | 193.8 | |||||||
| Adjusted net income margin from continuing operations | 9.4 | % | 8.5 | % | 8.6 | % | 6.3 | % | |||||||
| Weighted-average shares outstanding - diluted (in millions) | 163.5 | 138.4 | 155.5 | 138.9 | |||||||||||
| Adjusted net income per share - diluted from continuing operations (non-GAAP) | $ | 0.59 | $ | 0.51 | $ | 2.14 | $ | 1.40 | |||||||
| Net income per share - diluted from continuing operations (GAAP) | $ | 0.06 | $ | 0.29 | $ | 0.60 | $ | 0.44 | |||||||
__________
(1) Net income from continuing operations attributable to Colfax Corporation for the respective periods is calculated using Net income from continuing operations less the continuing operations component of the income attributable to noncontrolling interest, net of taxes, of
(2) Restructuring and other related charges includes
(3) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations for all periods presented.
(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.
(5) For the three months and year ended December 31, 2021, Strategic transaction costs includes costs related to the proposed separation of our fabrication technology and medical technology businesses, and certain transaction and integration costs related to recent acquisitions. For the three months and year ended December 31, 2020, Strategic transaction costs includes costs incurred for the acquisition of DJO.
(6) The effective tax rates used to calculate adjusted net income and adjusted net income per share were
Colfax Corporation
Reconciliation of GAAP to Non-GAAP Financial Measures
Dollars in millions
(Unaudited)
| Three Months Ended | Year Ended | ||||||||||||||
| December 31, 2021 | December 31, 2020 | December 31, 2021 | December 31, 2020 | ||||||||||||
| (Dollars in millions) | |||||||||||||||
| Net income from continuing operations (GAAP) | $ | 11.5 | $ | 41.5 | $ | 98.7 | $ | 64.1 | |||||||
| Income tax expense (benefit) | 28.3 | (8.7) | 66.7 | (6.1) | |||||||||||
| Pension settlement gain | — | — | (11.2) | — | |||||||||||
| Interest expense, net | 15.6 | 25.6 | 72.6 | 104.3 | |||||||||||
| Debt extinguishment charges | — | — | 29.9 | — | |||||||||||
| Restructuring and other related charges(1) | 16.9 | 16.5 | 32.9 | 45.0 | |||||||||||
| MDR and other costs(2) | 2.4 | 2.4 | 7.9 | 6.9 | |||||||||||
| Strategic transaction costs(3) | 16.7 | (0.4) | 44.0 | 2.8 | |||||||||||
| Acquisition-related amortization and other non-cash charges(4) | 44.8 | 35.8 | 163.6 | 143.9 | |||||||||||
| Adjusted EBITA (non-GAAP) | $ | 136.1 | $ | 112.8 | $ | 505.1 | $ | 361.0 | |||||||
| Net income margin from continuing operations (GAAP) | 1.1 | % | 5.0 | % | 2.6 | % | 2.1 | % | |||||||
| Adjusted EBITA margin (non-GAAP) | 13.3 | % | 13.6 | % | 13.1 | % | 11.8 | % | |||||||
__________
(1) Restructuring and other related charges includes
(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations for all periods presented.
(3) For the three months and year ended December 31, 2021, Strategic transaction costs includes costs related to the Separation, and certain transaction and integration costs related to recent acquisitions. For the three months and year ended December 31, 2020, Strategic transaction costs includes costs incurred for the acquisition of DJO.
(4) Includes amortization of acquired intangibles and fair value charges on acquired inventory.
Colfax Corporation
Reconciliation of GAAP to non-GAAP Financial Measures
Change in Sales
Dollars in millions
(Unaudited)
| Net Sales | ||||||||||||||||||||
| Fabrication Technology | Medical Technology | Total Colfax | ||||||||||||||||||
| $ | Change % | $ | Change % | $ | Change % | |||||||||||||||
| For the three months ended December 31, 2020 | $ | 518.6 | $ | 309.5 | $ | 828.1 | ||||||||||||||
| Components of Change: | ||||||||||||||||||||
| Existing businesses(1) | 114.1 | 22.0 | % | 34.5 | 11.1 | % | 148.6 | 17.9 | % | |||||||||||
| Acquisitions(2) | 0.5 | 0.1 | % | 57.1 | 18.4 | % | 57.6 | 7.0 | % | |||||||||||
| Foreign currency translation(3) | (9.0) | (1.7 ) % | (2.0) | (0.6) % | (11.0) | (1.3) % | ||||||||||||||
| 105.6 | 20.4 | % | 89.6 | 28.9 | % | 195.2 | 23.6 | % | ||||||||||||
| For the three months ended December 31, 2021 | $ | 624.2 | $ | 399.1 | $ | 1,023.3 | ||||||||||||||
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price and volume. Includes the favorable sales impact of approximately
(2) Represents the incremental sales in comparison to the portion of the prior period during which we did not own the business.
(3) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
| Net Sales | |||||||||||||||||
| Fabrication Technology | Medical Technology | Total Colfax | |||||||||||||||
| $ | Change % | $ | Change % | $ | Change % | ||||||||||||
| For the year ended December 31, 2020 | $ | 1,950.1 | $ | 1,120.7 | $ | 3,070.8 | |||||||||||
| Components of Change: | |||||||||||||||||
| Existing businesses(1) | 456.6 | 23.4 | % | 154.3 | 13.8 | % | 610.9 | 19.9 | % | ||||||||
| Acquisitions(2) | 2.1 | 0.1 | % | 139.5 | 12.4 | % | 141.6 | 4.6 | % | ||||||||
| Foreign currency translation(3) | 19.3 | 1.0 | % | 11.7 | 1.0 | % | 31.0 | 1.0 | % | ||||||||
| 478.0 | 24.5 | % | 305.5 | 27.2 | % | 783.5 | 25.5 | % | |||||||||
| For the year ended December 31, 2021 | $ | 2,428.1 | $ | 1,426.2 | $ | 3,854.3 | |||||||||||
(1) Excludes the impact of foreign exchange rate fluctuations and acquisitions, thus providing a measure of growth due to factors such as price and volume.
(2) Represents the incremental sales in comparison to the portion of the prior period during which we did not own the business.
(3) Represents the difference between prior year sales valued at the actual prior year foreign exchange rates and prior year sales valued at current year foreign exchange rates.
Colfax Corporation
Reconciliation of GAAP to non-GAAP Financial Measures
Free Cash Flow
Dollars in millions
(Unaudited)
| Year Ended | |||
| December 31, 2021 | |||
| Net cash provided by operating activities (GAAP) | $ | 356.1 | |
| Purchases of property, plant and equipment (GAAP) | (104.2) | ||
| Payments related to the Separation | 22.2 | ||
| Proceeds from sale of certain properties(1) | 3.2 | ||
| Free cash flow (non-GAAP) | $ | 277.3 | |
(1) Includes proceeds from the sale of certain properties related to restructuring efforts for which previous cash outlays were included in Net cash provided by operating activities.
Colfax Corporation
Consolidated Balance Sheets
Dollars in thousands, except share amounts
(Unaudited)
| December 31, 2021 | December 31, 2020 | ||||||
| ASSETS | |||||||
| CURRENT ASSETS: | |||||||
| Cash and cash equivalents | $ | 719,370 | $ | 97,068 | |||
| Trade receivables, less allowance for credit losses of | 638,700 | 517,006 | |||||
| Inventories, net | 776,295 | 564,822 | |||||
| Prepaid expenses | 78,186 | 69,515 | |||||
| Other current assets | 90,728 | 113,418 | |||||
| Total current assets | 2,303,279 | 1,361,829 | |||||
| Property, plant and equipment, net | 521,391 | 486,960 | |||||
| Goodwill | 3,467,295 | 3,314,541 | |||||
| Intangible assets, net | 1,675,462 | 1,663,446 | |||||
| Lease asset - right of use | 184,429 | 173,942 | |||||
| Other assets | 363,489 | 350,831 | |||||
| Total assets | $ | 8,515,345 | $ | 7,351,549 | |||
| LIABILITIES AND EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Current portion of long-term debt | $ | 8,314 | $ | 27,074 | |||
| Accounts payable | 504,173 | 330,251 | |||||
| Accrued liabilities | 511,097 | 454,333 | |||||
| Total current liabilities | 1,023,584 | 811,658 | |||||
| Long-term debt, less current portion | 2,078,679 | 2,204,169 | |||||
| Non-current lease liability | 145,326 | 139,230 | |||||
| Other liabilities | 606,323 | 608,618 | |||||
| Total liabilities | 3,853,912 | 3,763,675 | |||||
| Equity: | |||||||
| Common stock, | 156 | 118 | |||||
| Additional paid-in capital | 4,544,211 | 3,478,008 | |||||
| Retained earnings | 589,024 | 517,367 | |||||
| Accumulated other comprehensive loss | (516,013) | (452,106) | |||||
| Total Colfax Corporation equity | 4,617,378 | 3,543,387 | |||||
| Noncontrolling interest | 44,055 | 44,487 | |||||
| Total equity | 4,661,433 | 3,587,874 | |||||
| Total liabilities and equity | $ | 8,515,345 | $ | 7,351,549 | |||
Colfax Corporation
Consolidated Statements of Cash Flows
Dollars in thousands
(Unaudited)
| Year Ended | |||||||
| 2021 | 2020 | ||||||
| Cash flows from operating activities: | |||||||
| Net income | $ | 76,278 | $ | 45,771 | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
| Depreciation, amortization and other impairment charges | 262,919 | 246,229 | |||||
| Stock-based compensation expense | 35,350 | 28,911 | |||||
| Non-cash interest expense | 4,752 | 5,739 | |||||
| Debt extinguishment charges | 29,870 | — | |||||
| Deferred income tax benefit | (22,188) | (29,218) | |||||
| Gain on sale of property, plant and equipment | (2,573) | (491) | |||||
| Pension settlement gain | (11,208) | — | |||||
| Changes in operating assets and liabilities: | |||||||
| Trade receivables, net | (110,985) | 42,688 | |||||
| Inventories, net | (129,967) | 23,787 | |||||
| Accounts payable | 178,467 | (30,747) | |||||
| Other operating assets and liabilities | 45,384 | (30,734) | |||||
| Net cash provided by operating activities | 356,099 | 301,935 | |||||
| Cash flows from investing activities: | |||||||
| Purchases of property, plant and equipment | (104,237) | (114,785) | |||||
| Proceeds from sale of property, plant and equipment | 7,033 | 9,552 | |||||
| Acquisitions, net of cash received, and investments | (223,272) | (69,846) | |||||
| Net cash used in investing activities | (320,476) | (175,079) | |||||
| Cash flows from financing activities: | |||||||
| Payments under term credit facility | — | (40,000) | |||||
| Proceeds from borrowings on revolving credit facilities and other | 991,494 | 860,681 | |||||
| Repayments of borrowings on revolving credit facilities and other | (417,526) | (938,997) | |||||
| Repayments of borrowings on senior notes | (700,000) | — | |||||
| Payment of debt issuance costs | — | (4,560) | |||||
| Proceeds from issuance of common stock, net | 745,179 | 3,500 | |||||
| Payment of debt extinguishment costs | (24,375) | — | |||||
| eferred consideration payments and other | (9,866) | (12,275) | |||||
| Net cash provided by (used in) financing activities | 584,906 | (131,651) | |||||
| Effect of foreign exchange rates on Cash and cash equivalents and Restricted Cash | (2,228) | (3,768) | |||||
| Increase (decrease) in Cash and cash equivalents and Restricted cash | 618,301 | (8,563) | |||||
| Cash and cash equivalents and Restricted Cash, beginning of period | 101,069 | 109,632 | |||||
| Cash and cash equivalents and Restricted Cash, end of period | $ | 719,370 | $ | 101,069 | |||
FAQ
What were Colfax's adjusted earnings per share for Q4 2021?
When is the separation of Colfax into Enovis and ESAB expected to occur?
What are the projected sales growth rates for Enovis and ESAB in 2022?
How much operating cash flow did Colfax generate in 2021?
What was Colfax's Q4 2021 sales figure?
